Risk Factors of Follicular Lymphoma
- PMID: 22754588
- PMCID: PMC3384553
- DOI: 10.1517/17530059.2012.686996
Risk Factors of Follicular Lymphoma
Abstract
INTRODUCTION: Non-Hodgkin Lymphoma (NHL) is a heterogeneous group of malignancies with over thirty different subtypes. Follicular lymphoma (FL) is the most common form of indolent NHL and the second most common form of NHL overall. It has morphologic, immunophenotypic and clinical features significantly different from other subtypes. Considerable effort has been devoted to the identification of risk factors for etiology and prognosis of FL. These risk factors may advance our understanding of the biology of FL and have an impact on clinical practice. AREAS COVERED: The epidemiology of NHL and FL is briefly reviewed. For FL etiology and prognosis separately, we review clinical, environmental and molecular (including genetic, genomic, epigenetic and others) risk factors suggested in the literature. EXPERT OPINION: A large number of potential risk factors have been suggested in recent studies. However, there is a lack of consensus, and many of the suggested risk factors have not been rigorously validated in independent studies. There is a need for large-scale, prospective studies to consolidate existing findings and discover new risk factors. Some of the identified risk factors are successful at the population level. More effective individual-level risk factors and models remain to be identified.
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
Risk Factors of Non-Hodgkin Lymphoma.Expert Opin Med Diagn. 2011 Nov 1;5(6):539-550. doi: 10.1517/17530059.2011.618185. Expert Opin Med Diagn. 2011. PMID: 22059093 Free PMC article.
-
Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data.Leuk Lymphoma. 2020 Jan;61(1):75-83. doi: 10.1080/10428194.2019.1648804. Epub 2019 Aug 7. Leuk Lymphoma. 2020. PMID: 31389296
-
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.Expert Opin Drug Discov. 2016 Nov;11(11):1123-1130. doi: 10.1080/17460441.2016.1233174. Epub 2016 Sep 16. Expert Opin Drug Discov. 2016. PMID: 27598460 Review.
-
Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.Arch Med Res. 2015 Aug;46(6):454-61. doi: 10.1016/j.arcmed.2015.07.004. Epub 2015 Jul 31. Arch Med Res. 2015. PMID: 26235285
-
An analysis of genetic targets for guiding clinical management of follicular lymphoma.Expert Rev Hematol. 2020 Dec;13(12):1361-1372. doi: 10.1080/17474086.2020.1850252. Epub 2020 Dec 4. Expert Rev Hematol. 2020. PMID: 33176509 Review.
Cited by
-
Comparing R-Bendamustine vs. R-CHOP Plus Maintenance Therapy as First-Line Systemic Treatment in Follicular Lymphoma: A Multicenter Retrospective GELTAMO Study.Cancers (Basel). 2024 Mar 26;16(7):1285. doi: 10.3390/cancers16071285. Cancers (Basel). 2024. PMID: 38610963 Free PMC article.
-
Incidence and mortality trends and geographic patterns of follicular lymphoma in Canada.Curr Oncol. 2019 Aug;26(4):e473-e481. doi: 10.3747/co.26.4625. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548815 Free PMC article.
-
An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT.Curr Oncol. 2015 Aug;22(4):260-71. doi: 10.3747/co.22.2431. Curr Oncol. 2015. PMID: 26300664 Free PMC article.
-
Racial differences in three major NHL subtypes: descriptive epidemiology.Cancer Epidemiol. 2015 Feb;39(1):8-13. doi: 10.1016/j.canep.2014.12.001. Epub 2015 Jan 2. Cancer Epidemiol. 2015. PMID: 25560974 Free PMC article.
-
Four synchronous cancers in a patient with tongue pain as the only symptom.BMJ Case Rep. 2016 May 5;2016:bcr2015214047. doi: 10.1136/bcr-2015-214047. BMJ Case Rep. 2016. PMID: 27151050 Free PMC article.
References
-
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review. National Cancer Institute; Bethesda, MD: 1975–2008. based on November 2010 SEER data submission.
-
- Ekstrom-Smedby K. Epidemiology and etiology of Non-Hodgkin lymphoma: a review. Acta Oncol. 2006;45:258–271. Epidemiology of NHL and FL. - PubMed
-
- Jaffe ES, Harris NL, Stain H, et al. Tumors of haematopoietic and lymphoid tissues. IRAC; Lyon: 2001. World Health Organization of classification of tumors. WHO classification of FL.
-
- Turner JJ, Hughes AM, Kricker A, et al. WHO Non-Hodgkin’s Lymphoma classification by criterion-based report review followed by targeted pathology review an effective strategy for epidemiology studies. Cancer Epidemiology, Biomarkers & Prevention. 2005;14:2213–2219. - PubMed
-
- Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol. 2011;86:768–775. Recent comprehensive review of diagnosis and treatment. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources